Research programme: protein-protein interaction inhibitors - Priaxon/Ludwig-Maximilians-University
Latest Information Update: 23 Jul 2013
At a glance
- Originator Priaxon
- Developer Ludwig-Maximilians-University; Priaxon
- Class Small molecules
- Mechanism of Action Signal transduction pathway inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Cancer